- Home
- FIS vs ONC Comparison
FIS vs ONC Comparison
Compare FIS & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIS
- ONC
- Stock Information
- Founded
- FIS 1968
- ONC 2010
- Country
- FIS United States
- ONC Switzerland
- Employees
- FIS N/A
- ONC N/A
- Industry
- FIS Business Services
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- FIS Consumer Discretionary
- ONC Health Care
- Exchange
- FIS Nasdaq
- ONC Nasdaq
- Market Cap
- FIS 34.0B
- ONC 37.3B
- IPO Year
- FIS N/A
- ONC N/A
- Fundamental
- Price
- FIS $68.32
- ONC $341.63
- Analyst Decision
- FIS Buy
- ONC Strong Buy
- Analyst Count
- FIS 17
- ONC 10
- Target Price
- FIS $90.06
- ONC $340.70
- AVG Volume (30 Days)
- FIS 4.7M
- ONC 273.8K
- Earning Date
- FIS 11-03-2025
- ONC 11-11-2025
- Dividend Yield
- FIS 2.33%
- ONC N/A
- EPS Growth
- FIS N/A
- ONC N/A
- EPS
- FIS 0.20
- ONC N/A
- Revenue
- FIS $10,317,000,000.00
- ONC $4,562,002,000.00
- Revenue This Year
- FIS $5.07
- ONC $881.07
- Revenue Next Year
- FIS $4.40
- ONC N/A
- P/E Ratio
- FIS $337.29
- ONC N/A
- Revenue Growth
- FIS 3.55
- ONC 47.33
- 52 Week Low
- FIS $63.00
- ONC $170.99
- 52 Week High
- FIS $91.98
- ONC $355.30
- Technical
- Relative Strength Index (RSI)
- FIS 56.43
- ONC 58.55
- Support Level
- FIS $63.00
- ONC $334.53
- Resistance Level
- FIS $67.46
- ONC $355.30
- Average True Range (ATR)
- FIS 1.35
- ONC 7.35
- MACD
- FIS 0.62
- ONC -0.08
- Stochastic Oscillator
- FIS 89.38
- ONC 60.50
About FIS Fidelity National Information Services Inc.
Fidelity National Information Services provides core processing and ancillary services to banks, but its business has expanded over time. By acquiring SunGard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS was providing payment processing services for merchants and holding leading positions in the United States and United Kingdom. But the company sold off a majority interest in Worldpay and now has only a minority stake.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.